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ABSTRACT
Now that the reduction in beta-mass has been clearly established in humans
with type 2 diabetes mellitus (T2D), the debate focuses on the possible mechanisms
responsible for abnormal islet microenvironment, decreased beta-cell number and
impaired beta-cell function, and their multifactorial aetiologies. The informations
available in the Goto-Kakizaki (GK/Par line) rat, one of the best characterized
animal models of spontaneous T2D, are reviewed in such a perspective. We propose
that the defective beta-cell mass and function in the GK/Par model reflects the
complex interactions of three pathogenic players: i) several independent loci
containing genes responsible for some diabetic traits (but not decreased beta-cell
mass); (ii) gestational metabolic impairment inducing a programming of endocrine
pancreas (decreased beta-cell neogenesis) which is transmitted to the next
generation; and (iii) secondary (acquired) loss of beta-cell differentiation due to
chronic exposure to hyperglycaemia (glucotoxicity). An important message is that
the «heritable» determinants of T2D do not simply rely on genetic factors, but
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probably involve transgenerational epigenetic responses. Finally, studies from our
group have shown that pharmacological use of GLP-1 receptor agonist in vivo
during the GK prediabetes period, induced beta-cell regeneration through activation
of beta-cell replication and neogenesis, and doing so prevented the development
of hyperglycaemia. This suggests a novel application of GLP-1 receptor agonists to
the prevention of human diabetes by treatment of at risk individuals during the
prediabetic period. Since we also demonstrated that GLP-1 acutely restores the
glucose competence of the GK beta-cell, GLP-1 receptor agonists turn to be very
attractive tools for the treatment of the decreased beta-cell functioning mass as
encountered in T2D.
Key words: Type 2 diabetes.—GK rat.—Insulin secretion.—GLP-1R agonists.—
Beta-cell regeneration.
RESUMEN
De la patogénesis al tratamiento de la diabetes tipo 2.
El paradigma de la rata GK
Ahora que la reducción de la masa de la célula beta ha sido claramente estable-
cida en humanos con diabetes mellitas tipo 2 (T2D), el debate se focaliza sobre los
posibles mecanismos responsables de un microambiente anormal en el islote, del
decrecido número de células beta, del alterado funcionamiento de ellas y de sus
etiologías multifactoriales. Las eficaces informaciones proporcionadas por la rata
Goto-Kakizaki (línea GK), uno de los mejor caracterizados modelos animales de
T2D espontánea, están siendo revisadas para tales fines. Nosotros proponemos que
la defectuosa masa y función de la célula beta en el modelo GK reflejan unas
interacciones complejas de tres vertientes patogénicas: i) varios loci que contienen
genes responsables de algunos indicios diabéticos (pero no de decrecida masa de
célula beta); ii) daño metabólico gestacional que induce un programa de páncreas
endocrino (decrecida neogénesis de célula beta), lo cual es transmitido a la próxi-
ma generación, y iii) secundaria (adquirida) pérdida de diferenciación de célula
beta debida a una exposición crónica a hiperglucemia (glucotoxicidad). Un mensa-
je importante es que los determinantes «heredables» de T2D no descansan simple-
mente sobre factores genéticos, sino probablemente envuelven respuestas epigené-
ticas transgeneracionales.
Finalmente, estudios de nuestro grupo han mostrado que el uso farmacológico
de agonistas del receptor de GLP-1 in vivo, en el periodo de prediabetes de ratas
GK, inducían regeneración de célula beta, a través de la activación de la replica-
ción y neogénesis de célula beta y de esta forma prevenían el desarrollo de hiper-
glucemia. Esto sugiere una nueva aplicación del receptor agonista de GLP-1 para
la prevención de diabetes humana por el tratamiento con éste, durante el periodo
prediabético, a individuos de riesgo. Como nosotros mostramos, también, que el
GLP-1 restaura de forma acusada la sensibilidad a la glucosa de la célula beta GK,
los agonistas del receptor de GLP-1 vuelven a ser una herramienta atractiva para
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el tratamiento del decrecimiento de la masa funcionante de la célula beta lo cual
es encontrada en T2D.
Palabras clave: Diabetes tipo 2.—Rata GK.—Secreción de insulina.—Agonistas
GLP-1R.—Regeneración de células beta.
Diabetes mellitus is a heterogeneous group of disorders
characterized by high blood glucose levels. The pancreatic beta-cell
and its secretory product insulin are central in the pathophysiology
of diabetes (1). Type 1 or insulin-dependent diabetes mellitus results
from an absolute deficiency of insulin due to autoimmune beta-cell
destruction. In type 2, non-insulin-dependent diabetes mellitus (T2D),
liver, muscle and fat cells are resistant to insulin actions and the
compensatory attempt by the beta-cell to release more insulin is
not sufficient to maintain blood glucose levels within a normal
physiological range, finally leading to the functional exhaustion of
the surviving beta-cells (1). T2D is made up of multiple forms each
of which is characterized to variable degrees by insulin resistance
and beta-cell dysfunction, and which together lead to hyperglycemia.
At each end of this spectrum are single-gene disorders that affect the
ability of the beta-cell to secrete insulin or the ability of liver, muscle
and fat cells to respond to insulin’s actions.
BETA-CELL DYSFUNCTION AS A CAUSE FOR HUMAN
TYPE 2 DIABETES
In patients with recognized type 2 diabetes, abnormalities of
secretion are present together with insulin resistance and cause
glucose intolerance. So far, information related to the functional
characteristics of islets from T2D patients is limited. Several groups
(2, 3) have recently reported multiple abnormalities of insulin
secretion in islets isolated from T2D donors such as: reduced insulin
content, poor secretion in response to glucose (whereas leucine,
glutamine or arginine challenge remained effective) associated with
a marked alteration of mitochondrial function (diminished glucose
oxidation, lower ATP/ADP ratio, impaired hyperpolarization of
mitochondrial membrane, increased expression of UCP-2) and signs
of increased oxidative stress. Structural changes in the islets of T2D
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subjects have been also described including the arteriosclerosis,
deposition of amyloid associated fibrosis and fat infiltrations (4, 5).
The genetic basis of beta-cell dysfunction in this form of diabetes
(the most frequent one) is certainly more complex than in subjects
with MODY or mitochondrial diabetes: it involves both multiple
interacting genes and environmental factors, which determine
whether diabetes will develop and at what age.
The clustering of T2D in families and the high concordance rates
noted for identical vs. fraternal twins implies a genetic etiology.
However, after years of intensive work by many laboratories, there
has been little success identifying T2D susceptiblity genes in humans
(review in 6).
A role for maternal inheritance in T2D was first suggested
by epidemiological studies. Adult patients described as having
maturity-onset diabetes had a higher prevalence of T2D in the
maternal side over two generations compared to the paternal side
suggesting a higher maternal transmission (7). In addition, in
patients with gestational diabetes, higher frequency of diabetes
in mothers than in fathers was reported (8). The maternal influence
in the development of T2D has been reported in the majority of
studies (9). Although a few studies did not find a maternal effect,
none reported a higher paternal transmission. Foetal exposure to
T2D as an environmental factor that may explain the maternal
transmission of T2D, was first demonstrated in Pima Indians, a
population with the highest prevalence of T2D reported around the
world (10). In order to negate the confounding effect of genetic
factors related to T2D, the effect of in utero exposure to type 1
diabetes was recently studied in a group of adult offspring free from
immunological markers of type 1 diabetes: a 33% prevalence of IGT
was reported in offspring of mothers compared to none of the
offspring of fathers (control group) (11). Taken together, these
findings strongly suggest that in utero exposure to diabetes is
associated with abnormal glucose homeostasis in offspring of
diabetic mothers and may participate in the excess of maternal
transmission in T2D.
To sum-up, now that the reduction in beta-mass has been
repeatedly established in humans with T2D, the debate focuses on
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the possible mechanisms responsible for decreased beta-cell number
and impaired beta-cell function and their multifactorial aetiology.
Hazard of invasive sampling and lack of suitable non-invasive
methods to evaluate beta-cell mass and beta-cell functions are strong
limitations for studies of the living pancreas in human. In such a
perspective, appropriate rodent models are essential tools for
identification of the mechanisms that increase the risk of abnormal
beta-cell mass/function and of T2D. Some answers to these major
questions are available from studies using the Goto-Kakizaki (GK)
rat model of T2D and they are reviewed in the present paper. The
GK rat is a non obese substrain of Wistar rat origin, developing T2D
early in life. Mild fasting hyperglycaemia and postprandial glucose
intolerance are primarily due to impaired beta-cell mass and function
on the background of a polygenic inheritance. In addition, secondary
defects in beta-cell function and insulin action may superimpose
(e.g., due to chronic hyperglycaemia [glucotoxicity]). Since the GK
rat can be regarded as one of the best available rodent strains for the
study of inherited T2D, it is extensively used in preclinical diabetes
research.
THE GOTO-KAKIZAKI WISTAR (GK) RAT MODEL OF
SPONTANEOUS TYPE 2 DIABETES
Most rodent models used for studies of the inheritance of T2D
(ob/ob mouse, db/db mouse, ZDF rat, OLEFT rat) show association
of hyperglycaemia and obesity with insulin resistance. However, in
the inbred GK (Goto-Kakizaki) rat line and more specifically in our
colony (GK/Par subline) maintained since 1989, all rats are nonobese,
nonketotic, and display mild fasting hyperglycaemia. The GK line
was established by repeated inbreeding from Wistar (W) rats selected
at the upper limit of normal distribution for glucose tolerance (12-
14) (Figure 1).
The adult GK/Par body weight is 10-30% lower than that of age and
sex-matched control animals. In male GK/Par rats, non-fasting plasma
glucose levels are typically 10-14 mM (6-8 mM in age-matched Wistar
outbred controls). In female GK rats, somewhat lower plasma glucose
concentrations are noted. Non-fasting plasma insulin levels in GK rats
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FIGURE 1. Design for the production of spontaneously diabetic GK rat by
repetition of selective phenotyping: here is shown the distribution of the sum of
blood glucose values (Σ blood glucose) during a standardised oral glucose
tolerance test (OGTT) in original parent Wistar rats and F1 to F35 rats. The GK
rat line (Wistar strain) has been produced by Goto et al. in Tohoku University,
Sendaï, Japan, by selective breeding over many generations from a non diabetic
Wistar rat colony on the basis of glucose intolerance (12). The diabetic state was
reported to become stable after the 30 generations of selective crosses.
from all colonies have been found similar or somewhat increased as
compared to age-matched controls. During the long-term inbreeding
of GK rats (> 20 years) the animals have maintained rather stable
levels of glucose intolerance and impairment of glucose-induced
insulin response, also when studied in the various sublines of GK rats.
However, other characteristics such as beta cell number, insulin
content and islet metabolism have been reported to differ between
different subline colonies, suggesting that different local breeding
environment and/or newly introduced genetic changes account for
contrasting phenotypic properties, but it is not clear wether the
reported differences are artefactual or true. Signs of early neuropathy
(2 mo) have been reported in GK adult while nephropathy and
retinopathy develop late (12 mo). The VMH-lesioned GK rat displays
accentuated hyperglycaemia and hypertriglyceridaemia with visceral
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fat accumulation and both microangiopathy and macroangiopathy.
Figure 2 summarizes the GK/Par rat pathogenic sequence culminating
in the chronic hyperglycaemia at adult age.
FIGURE 2. Time-course of diabetes in the GK/Par rat model. Males and
females are similarly affected and their diabetic state is stable over 72 weeks of
follow up (13). In adult GK rats, plasma insulin release in vivo in response to i.v.
glucose is abolished (13). In vitro studies of insulin release with the isolated
perfused pancreas or with perifused islets indicate that both the early and late
phases of glucose-induced insulin release are markedly affected in the adult GK
rat. Concerning insulin action in adult GK rats, decreased insulin sensitivity has
been reported in the liver, in parallel to moderate insulin resistance in extrahepatic
tissues (muscles and adipose tissues) (13). Hyperglycaemia is preceded by a period
of normoglycaemia, ranging from birth to weaning (15). Therefore during this
period the young GK rats can be considered to be prediabetic.
WHAT IS WRONG IN THE BETA-CELL POPULATION
OF THE GK/PAR RAT ONCE DIABETES IS THERE?
Decreased beta-cell number
In the adult GK/Par, total pancreatic beta-cell mass and pancreatic
insulin stores are similarly decreased (by 60%) (15). This alteration of
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the beta-cell population cannot be ascribed to increased beta-cell
apoptosis but is related, at least partly, to significantly decreased beta-
cell replication (13). Moreover, the adult GK/Par pancreas exhibits two
different populations of islets: large islets which are disrupted by
connective tissue (15) and display heterogeneity in the staining of the
beta-cells, and small islets with heavily stained beta-cells and normal
architecture.
The islets of adult GK/Par rats show decreased beta-cell number
and low insulin content compared with control islets. The islet DNA
content was decreased to a similar extent, consistent with our
morphometric data, which indicates that there is no major change in
the relative contribution of beta-cells to total endocrine cells in the
GK islets. In addition, the insulin content, when expressed relative
to DNA, remains lower in GK islets than in control (inbred Wistar/
Par) islets, which supports some degranulation in the beta-cells of
diabetic animals (16).
Moreover, using a complementary approach that associated
gene expression analysis (Affymetrix microarrays), quantitative
RT-PCR and immunohistochemical studies of pancreata as a
function of hyperglycaemia duration, we have recently demonstrated
that an inflammatory reaction is associated with islet fibrosis
in 4-month-old diabetic GK rats according to a process reminiscent
of microangiopathy (17). These alterations worsened with
hyperglycaemia duration and might contribute to enhanced GK beta-
cell impairment.
Decreased beta-cell population due to early limitation of
beta-cell neogenesis
Extensive follow-up of the animals after delivery revealed that
GK/Par pups become overtly hyperglycaemic for the first time after
three to four weeks of age only. Nevertheless, total beta-cell mass in
GK neonates is clearly decreased (by 60%) when compared with
Wistar rats (Figure 2) (15). We first previously demonstrated that the
early beta-cell growth retardation in the GK/Par model cannot be
ascribed to decreased beta-cell replication, nor to increased apoptosis
(15). We therefore postulated that the recruitment of new beta-cells
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from the precursor pool was defective in the young GK rat. A
meaningful set of data from our group (18-20) suggests that the
permanently reduced beta-cell mass in the GK rat indeed reflects a
limitation of beta-cell neogenesis during early fetal life.
First, the comparative study of the development of GK and Wistar
pancreases indicates that the beta-cell deficit (reduced by more than
50%) starts as early as fetal age 16 days (E16) (19). The decreased
proliferation and increased apoptosis in the ductal compartment of
the pancreas where the putative endocrine precursor cells localize
suggests that the impaired development of the beta-cell in the GK
fetus could result from the failure of the proliferative and survival
capacities of the endocrine precursor cells. Importantly, recent data
from our group indicate that defective signalling through the Igf2/
Igf1-R pathway represents a primary anomaly since Igf2 and Igf1-R
protein expressions are already decreased within the GK pancreatic
rudiment at E13.5, at a time when beta-cell mass (first wave of beta
cell expansion) is in fact normal (21). Low levels of pancreatic of
Igf2 associated with beta-cell mass deficiency is maintained
thereafter within the fetal pancreas (22) (Figure 3). We also have
unpublished data related to crossbreeding protocols between non-
diabeticW and diabetic GK rats: at E18.5, Igf2 protein expression is
low in GK/GK, W/GK and GK/W pancreata, similar low values in
E18.5 crossed W/GK and GK/W fetuses, those values being close to
that observed in GK/GK fetuses of the same age. These findings
rather support the hypothesis that the pancreatic Igf2 anomaly in
the GK diabetic model is linked to a genetic determinism. This view
is also consistent with the results of genetic analyses that linked a
locus containing the gene encoding Igf2 to diabetes in the GK rat
(23). The Igf2 gene is subjected to paternal genomic imprinting (24).
However, because the Igf2 expression is similarly affected in fetuses,
regardless of whether the father is W or GK, we cannot conclude to
a simple change of Igf2 gene imprinting in the GK rat.
Second, to evaluate the capacity for beta-cell compensatory growth
during the neonatal period, we took advantage of the report that the
destruction of the beta-cell mass subsequent to streptozotocin
injection in the neonatal rat is followed by spontaneous regeneration
through both differentiation of precursor cells (neogenesis) and
increased proliferation of surviving beta-cells (18). Using such
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FIGURE 3. Schematic presentation of the defective early pancreatic
development in the GK/Par rat. Pancreatic cell proliferation and apoptosis and
were estimated at embryonic ages E13.5 and E18.5. Comparison of the dorsal
pancreatic buds in GK and Wistar (W) rats indicates that the differentiation of the
early endocrine cells which appear between E12-E14 is preserved in GK, the
number of insulin- or glucagon-expressing cells being similar to Wistar pancreases.
Analysis of cell proliferation and apoptosis revealed no differences between Wistar
and GK pancreases at this stage. By contrast at E18.5 onward, the number of
beta-cells differentiating from the ductal network is reduced by 74% in the GK rat.
The apoptotic cells in the E18.5 GK pancreas are not endocrine cells since we did
not detect TUNEL-positive cells expressing insulin or glucagon. Moreover these
undifferentiated pancreatic cells exhibit a decreased replicative activity. The
morphological analysis of the sections suggested that the apoptotic cells in the GK
pancreas are ductal cells. IGF-2 protein expression was decreased by 27% and
58% on E13.5 and E18.5 respectively, in GK pancreatic rudiments as compared to
W controls. IGF-1R protein expression was decreased by 42% and 34% on E13.5
and E18.5 respectively in GK pancreatic rudiment as compared to W controls.
Therefore, the defective IGF2 and IGF1-R protein expression within the GK
pancreatic rudiment (E 13.5) precedes the beta-cell mass anomaly. ↑ represents an
increase, ↓ represents a decrease, and = means no change.
approach, we have shown that the regeneration of the beta-cell mass
was impaired in streptozotocin-treated newborn GK rats. Because the
index of beta-cell proliferation in the streptozotocin-treated GK and
Wistar neonates was identical, it was concluded that the impaired
beta-cell regeneration of the GK pancreas results from defective
neogenesis (18).
Third, similar conclusions were drawn from duct-cell remodelling
and beta-cell regeneration investigations after partial pancreatectomy
in the adult GK rat (20).
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Taken together, these data are consistent with the notion that a
poor proliferation and/or survival of the endocrine precursors during
foetal, neonatal and adult life will result in poor development of the
beta-cell mass, as well as a decreased pool of endocrine precursors
in the pancreas, and hence to an impaired capacity of regeneration
by neogenesis (either primary in the fetus or compensatory in the
newborn and the adult). Finally, the earliest alteration detected in
the GK/Par rat targets the size of the beta-cell population. It is
conceivable that some genes among those involved in the GK/Par
diabetes belong to the subset of genes controlling early beta-cell
development.
Functionally defective beta-cells
In adult GK/Par rats, the plasma insulin release in vivo in
response to intravenous glucose was lacking (12-14). In vitro studies
of insulin release with the isolated perfused pancreas or with
perifused islets indicated that both the early and late phases of
glucose-induced insulin release were markedly affected in the adult
GK/Par rat. We have shown that impaired glucose-induced insulin
release in GK/Par islets was associated with perturbation of multiple
intracellular sites. Since this aspect has been recently and extensively
reviewed by us and others (13, 14), it will not be further considered
in this paper. Figure 4 illustrates a compendium of the abnormal
intracellular sites so far identified in the diabetic GK beta-cell.
WHAT ARE THE MECHANISMS THAT UNDERLIE THE
PROGRAMMING OF THE GK BETA-CELL DYSFUNCTIONS?
Is beta-cell functional failure due to the abnormal metabolic
environment (gluco-lipotoxicity)?
In the GK/Par rat, basal hyperglycaemia and normal to very mild
hypertriglyceridaemia are observed only after weaning (13, 15). The
onset of a profound alteration in glucose-stimulated insulin secretion
by the GK beta-cell (after weaning) is time-correlated with the
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FIGURE 4. Model for defective glucose-induced insulin release and the
abnormal intracellular sites identified in the diabetic GK beta-cell (13).
Impaired insulin response to glucose may be attributed to impaired elevation of
intracellular [Ca2+]i, which is a consequence of the failure by glucose to augment
L-type Ca2+ channel activity, owing to insufficient plasma membrane
depolarization reflecting impaired closure of the ATP-sensitive K+ channels; this is
the result of insufficient cytosolic ATP generation by glucose. Abnormal Ca2+
handling by the endoplasmic reticulum in response to high glucose may also
contribute to the defective Ca2+ signalling. The sequestration of calcium by
endoplasmic reticulum during high glucose exposure (attributed to activation of
the calcium-ATPases, SERCAs) may be impaired in the GK beta-cell. Impaired
calcium sequestration could also occur because of insufficient cytosolic ATP
generation in response to high glucose. In GK islets, glucose fails to increase
inositol-phosphate (IP3) accumulation. This is linked to an anomaly in targeting
the phosphorylation of phosphoinositides: the activity of phosphatidyl-inositol
kinase, the first of the two phosphorylating activities responsible for generating
phosphatidyl-inositol biphosphate, is reduced. Moreover, deficient calcium handling
and ATP supply in response to glucose probably contributes to abnormal
activation of PI kinases and phospholipase C. Concerning cAMP, it is remarkable
that its intracellular content is high in GK β-cells already at low glucose. This is
related to increased expression of the cyclase isoforms 1, 2, 3 and of the Gsα and
Gαolf proteins. Furthermore, cAMP is not further enhanced at increasing glucose
concentrations (at variance with the situation in normal beta-cells). Moreover,
reduced levels of several exocytotic SNARE proteins including VAMP-2, syntaxin
1A and SNAP-25, have been demonstrated in GK islets. We also recently found
that the assembly/disassembly of the cortical actin cytoskeleton beneath the plasma
membrane, is functionally abnormal in GK islets. Where data are available, the
impaired sites in the GK beta-cell are indicated with a symbol:
Abbreviations: AC, adenylates cyclases; Gs, Gq: heterotrimeric G proteins;
PI kinase, phosphatidylinositol-kinase; SERCA3, type3 calcium-ATPase;
SNAP, soluble NSF attachment protein; tSNARE, v-SNARE: SNARE proteins
(syntaxin, SNAP-25); VDCC, L-type calcium chanel.
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exposure to the diabetic milieu. These changes in islet function can
be ascribed, at least in part, to a loss of differentiation of beta-cells
chronically exposed to even mild chronic hyperglycaemia and
elevated plasma non-esterified fatty acids, a process referred to as
«gluco-lipotoxicity». When studied under in vitro static incubation
conditions, islets isolated from normoglycaemic (prediabetic) GK/
Par pups, amplified their secretory response to high glucose, leucine
or leucine plus glutamine to the same extent as Wistar islets (13).
Therefore, there does not exist a major intrinsic secretory defect
in the prediabetic GK/Par beta-cell, which can be considered as
normally glucose-competent at this stage. Such a view is supported
by the recent reports that chronic treatment of GK rats with phlorizin
partially improved glucose-induced insulin release (25, 26, Bailbé
and Portha, unpublished data), while hyperlipidaemia induced by
high-fat feeding markedly impaired insulin secretion (27).
Consequently, the lack of beta-cell reactivity to glucose, as seen
during the adult period when the GK/Par rats are hyperglycaemic
in the basal state, represents an acquired defect mainly related to
glucotoxicity.
Which determinants (morbid genes vs environment) for early
deficiency of the beta-cell mass in the GK/Par model?
Concerning the potential maternal influence on the development
of T2D in the GK model, Gauguier et al. (28) reported that adult
offspring of GK females crossed with Wistar males have a more
marked hyperglycaemia than adult offspring of Wistar females
crossed with GK males, suggesting higher maternal inheritance.
However, this conclusion was not confirmed in other studies and
cross-breeding experiments do not overcome the difficulty to isolate
the respective contribution of genetic vs. intrauterine environmental
factors. Recently, Gill-Randall et al. (29) developed an embryo
transfer system to examine more convincingly that major point. First,
these authors showed that offspring from GK embryos transferred
in the uterus of euglycaemic W mother still develop T2D when
adults, therefore highlighting a role for genetic factors. Second, they
showed that offspring from W embryos reared in hyperglycaemic
GK mothers were significantly hyperglycaemic at adulthood (29).
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Thus, in W rats with no genetic risk of diabetes, exposure to
hyperglycaemia in utero (as seen in the GK pregnant mother)
increases the risk of hyperglycaemia in adult life (29), this clearly
illustrating a diabetogenic role for the GK intrauterine environment.
Concerning the impact of maternal hyperglycaemia (as induced
experimentally in the rat by streptozotocin (30) or glucose infusion
(31) on beta-cell function specifically, it has been long recognized that
it persists into adult life and the second and third generation
offsprings. Another recent illustration is offered by observations in rat
pups reared artificially on a high carbohydrate (HC) milk formula
(32): such alteration of nutrition during the suckling period only,
induces persistent adaptation of energy metabolism in adulthood
(obesity, glucose intolerance, impaired insulin secretion) and the HC
fed females spontaneously transmitted their metabolic characteristics
to their progeny without the pups themselves having to undergo any
nutritional treatment (32). Taken as a whole, information from the HC
rat pup model (32) and from the offspring of mildly hyperglycaemic
rat mothers (33) suggests that hyperglycaemia experienced during the
foetal and/or early postnatal life contributes to programming of
the endocrine pancreas. Such a scenario also potentially applies to the
GK/Par model, as GK/Par mothers are slightly hyperglycaemic
through their gestation and during the suckling period. Therefore, the
gestational diabetic pattern of the GK/Par mothers may contribute per
se (besides inherited disease genes) to establish and/or maintain the
transmission of endocrine pancreas programming from one GK/Par
generation to the next one. By such mechanism, the GK/Par rat can
be viewed as a model of developmental programming for T2D
(associated to programming for low beta-cell mass), with a stable
transgenerational transmission.
Two functional point mutations in the promoter region of the
adenyl cyclase type 3 (AC3) gene have been reported in both islets
and peripheral blood of GK rats in the Stockholm colony and are
associated to GK beta-cell AC3 over expression and increased cAMP
generation (34). The contribution if any, of such a mutation to the
GK beta-cell growth defect is so far unknown.
Gauguier et al. (23) using a quantitative trait locus (QTL)
approach, have identified six independently segregating loci
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containing genes regulating fasting plasma glucose and insulin levels,
glucose tolerance, insulin secretion and adiposity in GK/Par rats.
The same conclusion was drawn by Galli et al. (35) using GK from
the Stockholm colony. This established the polygenic inheritance
of diabetes-related parameters in the GK rat. Both studies found
the strongest evidence of linkage between glucose tolerance and
markers spanning a region on rat chromosome 1, called Niddm1
locus. While it must be recognized that many of the glucose-
controlling locus variants reported (23, 35, 36) were associated in
fact with hyperinsulinaemia or enhanced insulin secretion, more
recent works using congenic technology have identified on the
Niddm1i locus a 3.5 cM region containing approximately ten genes,
as a major susceptibility locus for defective insulin secretion (37).
However, no QTL association with beta-cell mass or beta-cell size is
found in the GK/Par rat (Ktorza and Gauguier, unpublished data).
Therefore, the likehood that a genotype alteration contributes to the
low beta-cell mass phenotype in the GK/Par rat, is reduced. The
raised question to be answered now is the following: does epigenetic
perturbation of gene expression occur in the developing GK pancreas
and does it contribute to the alteration of early beta-cell growth? igf2
and igf1r genes are good candidates for such a perspective.
WHICH THERAPEUTIC FOR A DECREASED BETA-CELL
FUNCTIONAL MASS AS SEEN IN THE GK RAT? A ROLE
FOR GLP-1 RECEPTOR AGONISTS
Current therapy of T2D includes a modification of life style such
as diet and exercise and the use of a variety of pharmacological
agents that target increased insulin secretion, decreased hepatic
glucose production and increased insulin action. Despite these
approaches, a number of T2D patients may require exogenous
insulin. Facilitation of T2D treatment may be obtained through beta-
cell transplantation, or on more prospective basis, beta-cell mass
expansion after stimulation of beta-cell regeneration/neogenesis in
the diabetic patients. Indeed, the emerging understanding of beta-
cell growth in the adult, from precursor cells found in the pancreatic
ducts, hold the promise of developing new strategies for stimulating
beta-cell regeneration. Such approach may involve the delivery of
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appropriate growth factors to these progenitor cells to obtain a full
beta-cell phenotype. GLP-1 could be one of the most promising
candidate for doing so.
GLP-1 is an incretin and is produced by the L-cells of the intestine
(review in 38). Since its discovery, GLP-1 has received much
attention as a possible new treatment for type 2 diabetes. GLP-1
stimulates insulin secretion and biosynthesis and inhibits glucagon
release and both these effects are glucose dependent and therefore
represent a very safe way of lowering increased blood glucose (38).
A key factor limiting the therapeutic potential of GLP-1 is, however,
its very short half-life in vivo (38). Therefore, GLP-1 analogs with
longer duration of in vivo actions have been studied. Exendin-4
(Ex-4; now marketed as an antidiabetic under the name exenatide),
a peptide isolated from the salivary secretions of Heloderma
suspectum is one of them (38). Ex-4 shows 53% amino acid identity
to GLP-1 and similar insulinotropic action compared to GLP-1 (38).
Lately, it was demonstrated that both GLP-1 and Ex-4 were able to
stimulate growth and proliferation of pancreatic beta-cells in vitro
and in vivo in adult rodents (38).
Taking advantage of the opportunity that the GK model is a
unique one to test the effect of any pharmacological agent suspected
to target the beta cell growth and function under conditions of
spontaneous T2D, we evaluated if a GLP-1 or Ex-4 treatment applied
during few days in pre-diabetic stage in GK rats would halt or
prevent the pathological progression.
Accordingly, we have raised the question of what is the impact of
GLP-1 or Ex-4 treatment, first in term of beta-cell mass enlargement
and long-term improvement of glucose homeostasis in the GK model.
To address this issue, we have investigated the capacity of GLP-1 or
Ex-4 treatment to promote beta-cell proliferation in GK rats during
the pre-diabetic stage and thereby to prevent the pathological
progression of the T2D when animals become adults. To this end,
GK rats were submitted to GLP-1 or Ex-4 injection from postnatal
day 2 to day 6 only, and their body weight and plasma glucose and
insulin levels were examined longitudinally from weaning to
adulthood (39). Their beta-cell mass and pancreatic functions were
tested on day 7 and later on, at 2 months. Both treatments enhanced,
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on day 7, pancreatic insulin contents and total beta-cell mass by
stimulating beta-cell neogenesis and beta-cell regeneration. Follow
up of biological characteristics from day 7 to adult age (2 months)
showed that both treatment exerted long-term favorable influence
on beta-cell mass and glycaemic control at adult age (Figure 5). As
compared to untreated GK rats, 2-month-old GLP-1 or Ex-4 treated
GK rats exhibited significantly decreased basal plasma glucose. Their
glucose-stimulated insulin secretion, in vivo after intravenous glucose
load or in vitro using isolated perfused pancreas, were improved.
Moreover, plasma glucose disappearance rate was increased in both
treated GK groups compared to untreated GK group (39). These
findings in the GK model indicate that a GLP-1 or Ex-4 treatment
limited to the pre-diabetic period, delays the installation and limits
the severity of T2D.
We have also raised the question of what is the acute impact of
GLP-1 in term of beta-cell secretory function in the GK model. To
that aim, we have determined the effect of an acute GLP-1 exposure
on GK islets. We first found that GLP-1 was able to restore the
glucose competence of the GK beta-cell with a clear return of
the biphasic pattern of insulin release (Figure 6). Then, we have
demonstrated that this is by a mechanism which mainly reflects an
enhanced efficacy of Ca2+ on exocytosis (in the absence of Ca2+
elevation) and directly relates to an enhanced production of cAMP
and overexpression of AC1, 2, and 3 isoforms and Gsα in the GK
beta-cells. Such a sensitization to GLP-1 allows acute normalization
of the defective glucose responsiveness of the GK beta-cell (40).
According to our preclinical studies in the GK model, the GLP-
1 receptor agonists therefore represent a class of compound with
unique property due to their beta-cell replenishing effect in
spontaneously diabetic rodents. They may prove invaluable agent
not only for treatment of yet installed human T2D but also for its
prevention.
In conclusion, the defective beta-cell mass and function in the
GK/Par model reflects the complex interactions of three pathogenic
players: i) several independent loci containing genes responsible
for some diabetic traits (but not decreased beta-cell mass); (ii)
gestational metabolic impairment inducing a programming of
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FIGURE 5. GLP-1 or Exendin-4 treatment promotes beta-cell proliferation in
GK rats during the pre-diabetic stage and thereby prevents the pathological
progression of the T2D when animals become adults. Left panel: Evolution of
post-absorptive basal plasma glucose levels of W, GK, GK/GLP-1 and GK/Ex-4
from 7 days to 2 months of age. Values are expressed as mean ± SEM. In each
group, 10 to 15 animals were studied. Right panel: Total pancreatic beta-cell mass
quantification in 60-day-old W, GK, GK/GLP-1 and GK/Ex-4 rats. Values are
expressed as mean ± SEM for 4 observations in each group. ** p<0.01; * p<0.05
compared with untreated GK rat.
endocrine pancreas (decreased beta-cell neogenesis) which is
transmitted to the next generation; and (iii) secondary (acquired)
loss of beta-cell differentiation due to chronic exposure to
hyperglycaemia (glucotoxicity). An important message is that the
«heritable» determinants of T2D are not simply dependant of genetic
factors, but probably involve transgenerational epigenetic responses.
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FIGURE 6. GLP-1 restores blunted glucose-stimulated insulin secretion by GK
islets. Wistar or GK islets were perifused with a medium containing 2.8 mM
Glucose (G). G16.7 and GLP-1 were added as indicated. A and B: [Ca2+]i values.
C and D: insulin secretion. Data are means of 4 to 8 experiments from three to
six different islet preparations in each group.
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